FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and psychoneurology, particularly to agents for treating multiple sclerosis.
EFFECT: composition (the solid oral dosage form) is applicable for sublingual, buccal delivery or gingival mucosal delivery of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide (Teriflunomide) as an active agent.
3 cl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING MULTIPLE SCLEROSIS (VERSIONS) | 2011 |
|
RU2471482C1 |
| PHARMACEUTICAL COMPOSITION POSSESSING THERAPEUTIC EFFECT ON DEMYELINATING DISEASES (VERSIONS) | 2015 |
|
RU2611415C1 |
| METHOD FOR PREPARING TERIFLUNOMIDE TABLETS | 2013 |
|
RU2536258C1 |
| SOLID PROLONGED-RELEASE DOSAGE FORM OF NON-STEROIDAL ANTI-INFLAMMATORY DRUG KETOPROFEN, METHOD FOR PREPARING IT | 2011 |
|
RU2448690C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING URINARY DISTURBANCES | 2012 |
|
RU2497504C1 |
| DOSAGE FORMS CONTAINING DOPAMINE AGONISTS FOR PARENTERAL ADMINISTRATION | 2009 |
|
RU2532347C2 |
| PHARMACEUTICAL COMBINATION CONTAINING VINPOCETINE AND BETAHISTINE FOR TREATING CEREBRAL CIRCULATORY DEPRESSION | 2008 |
|
RU2386439C2 |
| PEPTIDE FROM THE COMPOSITION OF THE IMMUNOGLOBULIN HUMAN HEAVY CHAIN, SUITABLE FOR TREATMENT OF MULTIPLE SCLEROSIS | 2016 |
|
RU2646817C1 |
| COMBINATION IN ORAL DISPERSIBLE FORM WITH THERAPEUTIC ACTION ON ACTIVATING AND INHIBITORY FUNCTIONS OF NERVOUS SYSTEM (VERSIONS) | 2011 |
|
RU2464013C1 |
| TRANSMUCOSAL SYSTEM OF DELIVERY OF MEDICAL PRODUCTS | 2004 |
|
RU2342953C2 |
